View Full Version : svenska adhd-grupper och webbsajter

08-05-04, 04:47 AM - svenska föreningen för barn, ungdomar och vuxna med något neuropsykiatriskt funktionshinder - svenska autismföreningen

08-06-04, 03:20 AM
"The Working Memory Training Company
Cogmed Cognitive Medical Systems AB (Cogmed) creates scientifically developed and clinically validated software-based training therapies for people with deficits in working memory (WM). The therapies are at the forefront of the emerging training paradigm, where the opportunities created by the human brain's newly proven plasticity, or ability to change, are put to clinical use. Cogmed intends to make its proprietary therapies the preferred treatment of attention deficits, world-wide.
The origin of Cogmed is research at the Karolinska Institute, the leading medical research center in Northern Europe. Cogmed was founded in 2001 by Karolinska Innovations AB (KIAB) and the key inventors, headed by Torkel Klingberg, MD, PhD. The company is based in Stockholm, Sweden.

First product launched
Cogmed has launched sales of RoboMemo, the company's first therapy for pediatric ADHD (Attention Deficit/Hyperactivity Disorder) in Sweden, after validation in a large multi-site study. The study showed very strong results. The ADHD market is large and growing rapidly. Cogmed can offer RoboMemo as a unique, effective and safe therapy in this attractive field.
Following highly promising pilot results in cognitive rehabilitation for stroke patients, a stroke therapy application is now in rapid development. Additional applications such as adult ADHD and age-related cognitive disorders are in research phase.

Rapid process from research to proven and safe therapy
Software-based training therapies from Cogmed combine the rigorous development and testing processes of therapy development with the speed of software creation. A structured process for bringing research findings into scientifically, clinically and commercially validated therapies has allowed Cogmed to go from research breakthrough to commercial product in less than three years.

Breakthrough in WM research opens new treatment options
Working memory capacity is the ability to retain and manipulate information during a short period of time. It is critical for attention. WM capacity can, for example, be measured by testing how many digits a person can repeat back after hearing them once. In daily life, we use the WM to remember plans or instructions of what to do next, in problem solving, and for controlling attention.

New research shows WM can be improved through training
WM capacity has generally been held to be a fixed property of the individual. However, the research team behind Cogmed has shown that this is not the case. WM capacity can be improved through correctly designed training. The change translates to strong improvements in attention, impulse inhibition and reasoning skills. This breakthrough paves the way for completely new therapies.

ADHD first market for Cogmed
RoboMemo is the first and only clinically validated non-pharmacological treatment of ADHD.

Working memory capacity core deficit in ADHD
ADHD is a condition of severe problems of inattention, impulse inhibition and hyperactivity. The disorder affects at least 3-5% of school-age children. This means 30-50.000 Swedish children with serious impairments in both academic performance and social functioning. Many of these problems persist into adulthood. New research has shown that the underlying problem in ADHD is often deficiencies in WM capacity.

ADHD problem in focus for medical and school professionals
ADHD is attracting increasing attention from the medical profession, school professionals and health authorities, as the suffering, costs and secondary effects caused by the disorder are better understood. There is a large and growing market for pharmaceutical products for ADHD, traditionally stimulant-based. There is also a brisk trade in various "alternative" methods, lacking research basis and clinical validation. There is a widely percieved need for effective, safe and proven treatments.

RoboMemo therapy for children with ADHD is Cogmed"s first product
Cogmed´s first product is RoboMemo, a software-based training program for children with ADHD. RoboMemo is a five-week training therapy of daily half hour sessions using a PC at home or in school. The training consists of specifically designed visuo-spatial and verbal WM training tasks, where the complexity level of the exercises is adjusted dynamically to create the training effect. The proprietary adjustment algorithm uses research learnings from studies on induced plasticity in motor training.

Effective training is an individualized premium service
The daily results are uploaded using an internet connection. Training progress is monitored online by a specialized user coach, a psychologist by training. The user coach provides feedback and motivation, and dynamically adjusts the individual's training regimen as needed.

RoboMemo therapy based on years of research and clinical tests
A prototype version of RoboMemo was tested in 2000 in a study involving 14 children with ADHD. The key findings were published in the Journal of Clinical and Experimental Neuropsychology in 2002 (Klingberg et al). The results were very encouraging and led to the creation of Cogmed, to secure resources for developing the prototype into a stable and scalable system, and to commercialize the breakthrough. The commercial potential in WM training therapies was evident to Karolinska Innovations, the department responsible for the commerzialization of research at the Karolinska Institute.

Further improvements through research on training data
All user training data is stored in a centralized data base that enables in-depth analysis of each treatment. The system provides tools for assessing impact and for establishing optimal individualized treatment plans. The value of this data base grows with each new user and provides Cogmed with a strong competitive tool.

The effect of training validated in large multi-site study
In 2002, a larger clinical trial was carried out. Independent, specialized clinicians at four different research hospitals across Sweden recruited and tested 52 children with ADHD. In a placebo controlled, double-blind, randomized trial, the impact of the RoboMemo therapy was studied. The treatment effect from the first study was confirmed, with significant improvement in attention and impulse control. The results are submitted for publication.
Equally important, parent and teacher ratings showed significant improvements in daily life. About 90% of the effect remained three months after the conclusion of training.

Working memory training in clinical practice
After successful limited test sales of RoboMemo during spring 2003, RoboMemo training is now a reality in clinical practice. The list of buyers - county councils, schools and families is growing. Interest and demand for more information about working memory training is strong among specialized physicians, psychologists and teachers.

Cognitive rehabilitation for stroke survivors next application
Creating an effective and proven method for cognitive rehabilitation of stroke patients opens up a potentially large market for Cogmed.

WM deficits central problem for stroke patients
WM deficits are a central problem for people who have suffered a stroke. The cognitive problems that follow from weak WM are a serious obstacle to all the available forms of rehabilitation. This means that improved WM capacity is the key to a successful return to normal life after a stroke. Today, there are no proven methods available for such cognitive rehabilitation.

Pilot study shows strong effect in rehabilitation after stroke
A first pilot study on WM training for stroke patients was carried out by Cogmed researchers in spring 2003, using the RoboMemo method. The results are very promising. All nine subjects showed significant improvements in WM capacity, and the results generalized to other tests and to perceived improvements in daily life. In a development project with a leading stroke clinic a training program called ReMemo, for adults with aquired brain injury has been developed. A second study with stroke patients is being carried out during 2004.

Successful start in Sweden
Sweden is a proof-of-concept market for Cogmed, and the company is now preparing the ground for establishing WM training overseas.
Intellectual property rights to the research, software, product, method and trademarks have been secured. The method will be turned into a franchise-based concept for specialized clinics, as one of several modes of distribution.

Team combining brain research, behavioral psychology and game design
Today Cogmed employs a strong team bringing very different fields of expertise into a powerful combination. Leading imaging-based cognitive neuroscience is merged with cognitive behavioral therapy. Creative game design for children meets advanced data base analysis, and the international business development plans are fed with the daily learnings from close interaction with children, parents, teachers and doctors."

information in swedish is available at:

08-06-04, 03:56 AM
vuxenprojektet vid bnk i göteborg - för vuxna med neuropsykiatriska funktionshinder som debuterat i barndomen.
projektansvarig är överläkare, professor christopher gillberg.

08-06-04, 08:36 AM
vuxenprojektet vid bnk i göteborg - för vuxna med neuropsykiatriska funktionshinder som debuterat i barndomen.
projektansvarig är överläkare, professor christopher gillberg.


Would you mind translating this for us?


08-06-04, 08:43 AM
vuxenprojektet vid bnk i göteborg - för vuxna med
neuropsykiatriska funktionshinder som debuterat i barndomen.
projektansvarig är överläkare, professor christopher gillberg.

the adults' project at the childrens' neuropsychiatric clinic in göteborg/gothenburg. for adults with neuropsychiatric conditions that manifested in childhood.

responsible for the project is med dr professor c. gillberg.[/QUOTE]

08-09-04, 11:24 AM
<TABLE cellSpacing=0 cellPadding=0 width=529 border=0><TBODY><TR><TD height=17>christopher gillberg
överläkare, professor i barn- och ungdomspsykiatri
<!-- Organistation: -->
</TD><TD height=17>

</TD></TR><TR><TD height=17>Besöksadress:

</TD><TD height=17>Se nedan

</TD></TR><TR><TD height=17>Postadress:

</TD><TD height=17>Göteborgs Universitet

</TD></TR><TR><TD height=17><!--Postadress2-->

</TD><TD height=17>Avd för barn- och ungdomspsyk

</TD></TR><TR><TD height=17><!--Postadress3-->

</TD><TD height=17>Kungsgatan 12

</TD></TR><TR><TD height=17><!--Postadress4-->

</TD><TD height=17>411 19 Göteborg

</TD></TR><TR><TD height=17>Telefon:

</TD><TD height=17>031-17 21 51

</TD></TR><TR><TD height=17>Fax:

</TD><TD height=17>031-17 21 69

</TD></TR><TR><!-- Ett radmellanrum --><TD height=10></TD></TR><TR><TD height=17>E-post:

</TD><TD height=17> (


08-09-04, 11:26 AM
svenny kopp

<TABLE cellSpacing=0 cellPadding=0 width=529 border=0><TBODY><TR><TD width="30%" height=17></TD><TD width="70%" height=17>Doktorand

</TD></TR><TR><TD height=17>Tjänsteställe: <!-- Organistation: -->

</TD><TD height=17>Avd för barn- och ungdomspsykiatri (

</TD></TR><TR><TD height=17>Besöksadress:

</TD><TD height=17>Se nedan

</TD></TR><TR><TD height=17>Postadress:

</TD><TD height=17>BNK (Barnneuropsykiatri)

</TD></TR><TR><TD height=17><!--Postadress2-->

</TD><TD height=17>Otterhällegatan 12 A

</TD></TR><TR><TD height=17><!--Postadress3-->

</TD><TD height=17>411 18 Göteborg

</TD></TR><TR><TD height=17>Telefon:

</TD><TD height=17>031-343 56 58

</TD></TR><TR><TD height=17>Fax:

</TD><TD height=17>031-84 89 32

</TD></TR><TR><TD vAlign=top>Arbetsuppgifter:

</TD><TD vAlign=top>Doktorand vid avd för barn- och ungdomspsykiatri. Handledare: Professor Christopher Gillberg. Överläkare vid Barnneuropsykiatriska kliniken, Drottning Silvias barn- och ungdomssjukhus

</TD></TR><TR><!-- Ett radmellanrum --><TD height=10></TD></TR><TR><TD height=17>E-post:

</TD><TD height=17> (